Affiliation:
1. University of Gondar comprehensive specialized hospital
2. University of Gondar
3. Bahir Dar University
Abstract
Abstract
Background: Recently, dolutegravir (DTG)-based combined therapy, a more effective and safer first-line antiretroviral therapy (ART), has been recommended by the World Health Organization (WHO) for the treatment of Human Immunodeficiency Virus (HIV) since July 2018. However, its effectiveness in CD4+ T-cells count recovery and viral load suppression has not been studied yet in Ethiopia, where HIV is endemic. Therefore, we aimed to assess the effect of DTG-based therapy on CD4+ T-cell count and viral load count among HIV-positive patients in Ethiopia.
Methods: A longitudinal prospective cohort study was conducted from July 2020–February 2021. 109 HIV-positive individuals who are ART naive but plan to initiate DTG-based therapy were recruited. HIV viral ribonucleic acid (RNA) copies were determined using a CD4+ T-cell count and quantitative polymerase chain reaction (PCR). To compute the difference in viral load and CD4+ T-cell counts between the baseline, 3rd, and 6th months, a Friedman test was used.
Results: The study included 109 HIV-positive people who had never received antiretroviral medication. Participants taking DTG-based treatment showed significantly decreasing median (IQR) values of viral load count (copies/mL) from 446,812 (237,649.5–732,994.5) at baseline to 34 (23.5–46) at 3 months and 0.0 (0–19) at 6 months of treatment follow-up. Although the treatment increases the proportion of participants with HIV-1 RNA 50 copies/mL from 0 (0% at baseline) to 87 (79.8%) and 100 (91.7%) at the 3rd and 6th months of treatment, respectively, On the other hand, the CD4+ T-cell count increased significantly during treatment: median (IQR): 209 (81.5–417.5) versus 291 (132–522) versus 378 (181.–632.5) cells/L at baseline, the 3rd and 6th months of the treatment follow-up period, respectively.
Conclusion: We found dolutegravir-based therapy was a promising option with high virological suppression rates and CD4+ T-cell count recovery demonstrating a restoration of cellular immunity. More over Viral load suppression rates were high after the initiation of the treatment.
Publisher
Research Square Platform LLC
Reference27 articles.
1. 1. Brehm TT, Franz M, Hüfner A, Hertling S, Schmiedel S, Degen O, et al. Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients. Med (United States). 2019;98(32):1–7.
2. 2. WHO. Clinical Guidelines: Antiretroviral Therapy. Consol Guidel Use Antiretrovir Drugs Treat Prev HIV Infect Recomm a Public Heal Approach [Internet]. 2016;(Second Edition):129. Available from: http://www.who.int/hiv/pub/arv/chapter4.pdf?ua=1
3. 3. Llibre JM, Cahn PE, Lo J, Barber TJ, Mussini C, van Welzen BJ, et al. Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review. Open Forum Infect Dis. 2022;9(4):2–10.
4. 4. Vitoria M, Hill A, Ford N, Doherty M, Clayden P, Venter F, et al. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: What are the issues? Aids. 2018;32(12):1551–61.
5. 5. Omondi FH, Sudderuddin H, Shahid A, Kinloch NN, Jones BR, Miller RL, et al. HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy. MBio. 2021;12(6):1–24.